A carregar...
Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
BACKGROUND: The epidermal growth factor receptor (EGFR) inhibitor, gefitinib, has been reported to successfully treat advanced non-small cell lung cancer patients with genetic mutations in EGFR. The aim of this study was to investigate the existence of EGFR mutations in carcinoma of esophagogastric...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3278359/ https://ncbi.nlm.nih.gov/pubmed/22252115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-7819-10-14 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|